How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
Certara2026 年 5 月 12 日
PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials
The FDA is shifting toward approving drugs based on a single pivotal trial supported by…
Certara2026 年 5 月 12 日
The one-trial era: what the FDA’s shift signals for the future of drug development
The FDA is shifting toward approving drugs based on a single pivotal trial supported by…
Certara2026 年 5 月 6 日
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
Certara2026 年 5 月 5 日
From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development
Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…
Certara2026 年 4 月 28 日
Top 10 Benefits of Simcyp® Simulator for Drug Development
JTVCdGVhbV9qdW1wX2xpc3QlNUQ= 2026 年 4 月 23 日 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…
Certara2026 年 4 月 23 日
Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations
Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…
Certara2026 年 4 月 2 日
